MediWound Management

Management criteria checks 0/4

MediWound's CEO is Ofer Gonen, appointed in Jun 2022, has a tenure of 2.42 years. total yearly compensation is $1.13M, comprised of 42.4% salary and 57.6% bonuses, including company stock and options. directly owns 1.04% of the company’s shares, worth €1.85M. The average tenure of the management team and the board of directors is 1.8 years and 2.3 years respectively.

Key information

Ofer Gonen

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	42.4%
CEO tenure	2.4yrs
CEO ownership	1.0%
Management average tenure	1.8yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ofer Gonen's remuneration changed compared to MediWound's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$1m	US$480k	-US$7m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$850k	US$253k	-US$20m

Compensation vs Market: Ofer's total compensation ($USD1.13M) is above average for companies of similar size in the German market ($USD786.80K).

Compensation vs Earnings: Ofer's compensation has increased whilst the company is unprofitable.

CEO

Ofer Gonen (51 yo)

2.4yrs

Tenure

US$1,133,000

Compensation

Mr. Ofer Gonen, B.Sc. MA Economic & Finance, serves as Chief Executive Officer at MediWound Ltd. since June 30, 2022. He was Chief Executive Officer of Clal Biotechnology Industries Ltd.from March 7, 2017...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ofer Gonen	Chief Executive Officer	2.4yrs	US$1.13m	1.04% € 1.9m
Hani Luxenburg	Chief Financial Officer	1.5yrs	US$244.00k	no data
Yaron Meyer	Executive VP	10.9yrs	US$379.00k	no data
Ety Klinger	Chief Research & Development Officer	10.5yrs	US$479.00k	no data
Lior Rosenberg	Co-Founder	23.8yrs	US$817.00k	no data
Shmulik Hess	COO & Chief Commercial Officer	less than a year	no data	no data
Liron Gal	Executive Director of Manufacturing Science & Technology	less than a year	no data	no data
Barry Wolfenson	Executive Vice President of Strategy & Corporate Development	1.7yrs	no data	no data
Robert Snyder	Chief Medical Officer	1.8yrs	no data	no data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: M8W's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Wills	Independent Director	7.5yrs	no data	no data
Nachum Shamir	Executive Independent Chairman	2.3yrs	no data	no data
David Fox	Independent Director	4.6yrs	no data	no data
Vickie Driver	Independent Director	7.5yrs	no data	no data
Samuel Moed	Member of Strategic Advisory Board	2.1yrs	no data	no data
Samuel Rubinstein	Independent Director	1.3yrs	no data	no data
John Lantis	Member of Strategic Advisory Board	2.1yrs	no data	no data

2.3yrs

Average Tenure

70yo

Average Age

Experienced Board: M8W's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

MediWound Management

Management criteria checks 0/4

Key information

Recent management updates

MediWound Ltd., Annual General Meeting, Jul 09, 2024

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

High number of new and inexperienced directors

High number of new directors

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

Recent updates

MediWound Ltd. Revises Revenue Guidance for 2024

MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

Second quarter 2024 earnings released: US$0.68 loss per share (vs US$0.099 profit in 2Q 2023)

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors

New minor risk - Profitability

MediWound Ltd., Annual General Meeting, Jul 09, 2024

First quarter 2024 earnings released: US$1.05 loss per share (vs US$0.44 loss in 1Q 2023)

MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024

New major risk - Share price stability

Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022)

MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024

Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study

Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns

Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.88 loss in 3Q 2022)

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023

MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults

High number of new and inexperienced directors

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.099 (vs US$0.92 loss in 2Q 2022)

MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023

MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan

Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.87 loss in 1Q 2022)

MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023

Full year 2022 earnings released: US$3.93 loss per share (vs US$3.48 loss in FY 2021)

MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd Gains Marketing Approval of NexoBrid® in India

High number of new directors

MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

Mediwound Ltd. Announces Management Changes

MediWound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns

MediWound Ltd. to Report Q2, 2022 Results on Aug 09, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd. Announces Positive Results from Its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

MediWound Ltd. Announces Appointment of Tzvi Palash as Chief Operating Officer

MediWound Ltd., Annual General Meeting, Jul 19, 2022

Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 1Q 2021)

MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex® for the Debridement of Venous Leg Ulcers

MediWound Ltd. to Report Q1, 2022 Results on May 17, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

U.S. Department of Defense Awards Defense Research Grant to Mediwound Ltd. for the Development of Nexobrid for the U.S. Army

MediWound Ltd. announced that it has received $9 million in funding from Biomedical Advanced Research And Development Authority

Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex for Debridement of Chronic Wounds

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.073 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 2Q 2020)

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

MediWound Completes Patient Enrollment for Interim Assessment of U.S. EscharEx Phase 2 Adaptive Design Study

First quarter 2021 earnings released: US$0.10 loss per share (vs US$0.09 loss in 1Q 2020)

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.076 profit in FY 2019)

Revenue beats expectations

MediWound Ltd. Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer